nivolumab
bms
['sclc', 'lcsm,(-blcsm)', 'nivolumab', 'nivo', 'nsclc']
pathologic response is key indicator of efs benefit with neoadjuvant nivolumab plus chemotherapy in resectable nsclc #asco22 #lcsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.